Home Articoli
HCV e nuovi farmaci: no a screening di popolazione, sì a misure di prevenzione

Il punto di...

HCV e nuovi farmaci: no a screening di popolazione, sì a misure di prevenzione
Alberto Donzelli

Evidence 2016;8(11): e1000156 doi: 10.4470/E1000156

Pubblicato: 21 novembre 2016

Copyright: © 2016 Donzelli. Questo è un articolo open-access, distribuito con licenza Creative Commons Attribution, che ne consente l’utilizzo, la distribuzione e la riproduzione su qualsiasi supporto esclusivamente per fini non commerciali, a condizione di riportare sempre autore e citazione originale.

1. Cattaneo A. Accesso alla terapia contro l’epatite C. La soluzione. Salute Internazionale, 4 luglio 2016.
2. Epatite C e nuovi farmaci. Una mozione Romani (Idv) e Dirindin (PD) sollecita il Governo a dare il via libera ai generici. Quotidiano Sanità, 27-7-2016.
3. Ad es. i deputati M5S Camera nella mozione presentata dalla capogruppo “attivare… uno screening di massa per l’individuazione di pazienti eleggibili ai quali rilasciare la relativa prescrizione medica”. Quotidiano Sanità, 13-10-2016.
4. Terrault NA et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 2013;57:881.
5. Istat 2016.
6. Bruno S et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 2016;64:1217.
7. Doha WTO Ministerial 2001: TRIPS WT/Min(01)/Dec/2 20 November 2001. Declaration on the TRIPS agreement and public health Adopted on 14 November 2001.
8. Koretz RL et al. Is widespread screening for hepatitis C justified? BMJ 2015;350:g7809.
9. Cartabellotta A. Efficacia e costo-efficacia del sofosbuvir nel trattamento dell’epatite C. Evidence 2015; 7:e1000111.
10. Wong GL-H et al. Incidences of all malignancies in patients with chronic hepatitis b receiving long-term oral nucleos(t)ide analogue treatment – a study of 45,299 subjects. Oral presentation to The International Liver Congress, Barcelona, Spain; 2016 April 13-17, Abstract Book.
11. Wong GL-H, comunicazione personale ad A. Donzelli a seguito di quesito, disponibile a richiesta.
12. Taida T et al. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. J Gastroenterol 2016 Jun 15.
13. Donzelli A. No allo screening per l’Helicobacter pylori per ridurre il cancro gastrico. Pillole di BPC 2014; 113. Fondazione Allineare Sanità e Salute.
14. Donzelli A. Helicobacter pylori. Eradication? Gastroenterology 2016;151:773.
15. Jespersen CM et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332: 22.
16. Cheng IJ et al. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. J Am Coll Cardiol 2015;66:2173.
17. Gambato M et al. Hepatitis C virus RNA persists in liver explants of most patients awaiting liver transplantation treated with an interferon-free regimen. Gastroenterology 2016; 151:633.
18. Mur RE. Expert meeting on the management of patients with HCV infection, Baveno 2016.
19. Di Novi C e Carrieri V. Epatite C: se il farmaco costa troppo per essere usato. lavoce.info 3-6-2016.
20. Donzelli A. Epatite C: prevenirla o frenarla con lo stile di vita. Pillole di ES 2015;105-106:1-4.
21. Agudo A et al. Impact of Cigarette Smoking on Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study J Clin Oncol 2012;30:4550.
22. Bhaskaran K et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 2014;384:755.
23. Polesel J et al The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009;20:353.
24. McGlynn K, AACR.
25. Wang P et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012;28:109.
26. Schutze M et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 2011;342:d1584.
27. Fedirko V et al. Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans. Ann Oncol 2013;24:543.
28. Duarte-Salles T et al. Dairy products and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2014;135:1662.
29. Lippi et al. Meat consumption and cancer risk: a critical review of published meta-analyses. Crit Rev Oncol Hematol 2016;97:1.
30. Bravi F et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007;46:430.
31. Saab S et al. Impact of coffee on liver diseases: a systematic review. Liver Int 2014;34:495.
32. Liu F et al. Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS One. 2015;10:e0142457.
33. Wijarnpreecha K et al. Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016 Sep 26.
34. Kennedy OJ et al. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther 2016; 43:562.
35. Fedirko V et al. Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC).Ann Oncol. 2013;24:2166.
36. Moore SC et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med 2016;176:816.